LY2922470

Cat. No.:	HY-19835
CAS No.:	1423018-12-5
Molecular Formula:	$C_{28}H_{29}NO_4S$
Molecular Weight:	475.6
Target:	Free Fatty Acid Receptor
Pathway:	GPCR/G Protein
Storage:	4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 125 mg/mL (262.83 mM)

* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions

Solvent / Mass / Concentration	1 mg	5 mg	10 mg
1 mM	2.1026 mL	10.5130 mL	21.0261 mL
5 mM	0.4205 mL	2.1026 mL	4.2052 mL
10 mM	0.2103 mL	1.0513 mL	2.1026 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.08 mg/mL (4.37 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.08 mg/mL (4.37 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.08 mg/mL (4.37 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

LY2922470 is a potent, selective and orally available agonist of the G protein-coupled receptor 40 (GPR40), with EC_{50}s of 7 nM, 1 nM and 3 nM for human GPR40, mouse GPR40 and rat GPR40, respectively. LY2922470 reduces glucose levels along with significant increases in insulin and GLP-1, is potential for the treatment of type 2 diabetes mellitus (T2DM)[1].

IC_{50} & Target

EC50⊠7 nM (human GPR40), 1 nM (mouse GPR40), 3 nM (rat GPR40)[1]

REFERENCES

[1]. Hamdouchi C, et al. The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470). J Med Chem. 2016 Dec 22;59(24):10891-10916.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA